171 related articles for article (PubMed ID: 30391478)
1. A power law function describes the time- and dose-dependency of Vγ9Vδ2 T cell activation by phosphoantigens.
Hsiao CC; Wiemer AJ
Biochem Pharmacol; 2018 Dec; 158():298-304. PubMed ID: 30391478
[TBL] [Abstract][Full Text] [Related]
2. A luciferase lysis assay reveals in vivo malignant cell sensitization by phosphoantigen prodrugs.
Li J; Lentini NA; Wiemer DF; Wiemer AJ
Biochem Pharmacol; 2019 Dec; 170():113668. PubMed ID: 31628909
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of a phosphoantigen prodrug that potently activates Vγ9Vδ2 T-lymphocytes.
Hsiao CH; Lin X; Barney RJ; Shippy RR; Li J; Vinogradova O; Wiemer DF; Wiemer AJ
Chem Biol; 2014 Aug; 21(8):945-54. PubMed ID: 25065532
[TBL] [Abstract][Full Text] [Related]
4. Phosphinophosphonates and Their Tris-pivaloyloxymethyl Prodrugs Reveal a Negatively Cooperative Butyrophilin Activation Mechanism.
Shippy RR; Lin X; Agabiti SS; Li J; Zangari BM; Foust BJ; Poe MM; Hsiao CC; Vinogradova O; Wiemer DF; Wiemer AJ
J Med Chem; 2017 Mar; 60(6):2373-2382. PubMed ID: 28218845
[TBL] [Abstract][Full Text] [Related]
5. Vγ9Vδ2 T cell activation by strongly agonistic nucleotidic phosphoantigens.
Moulin M; Alguacil J; Gu S; Mehtougui A; Adams EJ; Peyrottes S; Champagne E
Cell Mol Life Sci; 2017 Dec; 74(23):4353-4367. PubMed ID: 28669030
[TBL] [Abstract][Full Text] [Related]
6. The butyrophilin 3A1 intracellular domain undergoes a conformational change involving the juxtamembrane region.
Nguyen K; Li J; Puthenveetil R; Lin X; Poe MM; Hsiao CC; Vinogradova O; Wiemer AJ
FASEB J; 2017 Nov; 31(11):4697-4706. PubMed ID: 28705810
[TBL] [Abstract][Full Text] [Related]
7. Structure-Activity Relationships of Butyrophilin 3 Ligands.
Wiemer AJ
ChemMedChem; 2020 Jun; 15(12):1030-1039. PubMed ID: 32453919
[TBL] [Abstract][Full Text] [Related]
8. HMBPP Analog Prodrugs Bypass Energy-Dependent Uptake To Promote Efficient BTN3A1-Mediated Malignant Cell Lysis by Vγ9Vδ2 T Lymphocyte Effectors.
Kilcollins AM; Li J; Hsiao CH; Wiemer AJ
J Immunol; 2016 Jul; 197(2):419-28. PubMed ID: 27271567
[TBL] [Abstract][Full Text] [Related]
9. Diester Prodrugs of a Phosphonate Butyrophilin Ligand Display Improved Cell Potency, Plasma Stability, and Payload Internalization.
Singh U; Pawge G; Rani S; Hsiao CC; Wiemer AJ; Wiemer DF
J Med Chem; 2023 Nov; 66(22):15309-15325. PubMed ID: 37934915
[TBL] [Abstract][Full Text] [Related]
10. A Photo-Crosslinkable Biotin Derivative of the Phosphoantigen (E)-4-Hydroxy-3-Methylbut-2-Enyl Diphosphate (HMBPP) Activates Vγ9Vδ2 T Cells and Binds to the HMBPP Site of BTN3A1.
Mattarei A; Enzinger M; Gu S; Karunakaran MM; Kimmel B; Berner N; Adams EJ; Herrmann T; Amslinger S
Chemistry; 2017 Sep; 23(49):11945-11954. PubMed ID: 28631855
[TBL] [Abstract][Full Text] [Related]
11. A Structural Change in Butyrophilin upon Phosphoantigen Binding Underlies Phosphoantigen-Mediated Vγ9Vδ2 T Cell Activation.
Yang Y; Li L; Yuan L; Zhou X; Duan J; Xiao H; Cai N; Han S; Ma X; Liu W; Chen CC; Wang L; Li X; Chen J; Kang N; Chen J; Shen Z; Malwal SR; Liu W; Shi Y; Oldfield E; Guo RT; Zhang Y
Immunity; 2019 Apr; 50(4):1043-1053.e5. PubMed ID: 30902636
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and Metabolism of BTN3A1 Ligands: Studies on Modifications of the Allylic Alcohol.
Lentini NA; Schroeder CM; Harmon NM; Huang X; Schladetsch MA; Foust BJ; Poe MM; Hsiao CC; Wiemer AJ; Wiemer DF
ACS Med Chem Lett; 2021 Jan; 12(1):136-142. PubMed ID: 33488975
[TBL] [Abstract][Full Text] [Related]
13. Phosphonamidate Prodrugs of a Butyrophilin Ligand Display Plasma Stability and Potent Vγ9 Vδ2 T Cell Stimulation.
Lentini NA; Foust BJ; Hsiao CC; Wiemer AJ; Wiemer DF
J Med Chem; 2018 Oct; 61(19):8658-8669. PubMed ID: 30199251
[TBL] [Abstract][Full Text] [Related]
14. Phosphoantigen-induced conformational change of butyrophilin 3A1 (BTN3A1) and its implication on Vγ9Vδ2 T cell activation.
Gu S; Sachleben JR; Boughter CT; Nawrocka WI; Borowska MT; Tarrasch JT; Skiniotis G; Roux B; Adams EJ
Proc Natl Acad Sci U S A; 2017 Aug; 114(35):E7311-E7320. PubMed ID: 28807997
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Metabolism of BTN3A1 Ligands: Studies on Diene Modifications to the Phosphoantigen Scaffold.
Harmon NM; Poe MM; Huang X; Singh R; Foust BJ; Hsiao CC; Wiemer DF; Wiemer AJ
ACS Med Chem Lett; 2022 Feb; 13(2):164-170. PubMed ID: 35178171
[TBL] [Abstract][Full Text] [Related]
16. Stability and Efficiency of Mixed Aryl Phosphonate Prodrugs.
Foust BJ; Li J; Hsiao CC; Wiemer DF; Wiemer AJ
ChemMedChem; 2019 Sep; 14(17):1597-1603. PubMed ID: 31226236
[TBL] [Abstract][Full Text] [Related]
17. Butyrophilin 3A/CD277-Dependent Activation of Human γδ T Cells: Accessory Cell Capacity of Distinct Leukocyte Populations.
Nerdal PT; Peters C; Oberg HH; Zlatev H; Lettau M; Quabius ES; Sousa S; Gonnermann D; Auriola S; Olive D; Määttä J; Janssen O; Kabelitz D
J Immunol; 2016 Oct; 197(8):3059-3068. PubMed ID: 27619996
[TBL] [Abstract][Full Text] [Related]
18. In vivo gammadelta T cell priming to mycobacterial antigens by primary Mycobacterium tuberculosis infection and exposure to nonpeptidic ligands.
Poccia F; Malkovsky M; Pollak A; Colizzi V; Sireci G; Salerno A; Dieli F
Mol Med; 1999 Jul; 5(7):471-6. PubMed ID: 10449808
[TBL] [Abstract][Full Text] [Related]
19. Large-scale expansion of Vγ9Vδ2 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor-modified effector cells.
Xiao L; Chen C; Li Z; Zhu S; Tay JC; Zhang X; Zha S; Zeng J; Tan WK; Liu X; Chng WJ; Wang S
Cytotherapy; 2018 Mar; 20(3):420-435. PubMed ID: 29402645
[TBL] [Abstract][Full Text] [Related]
20. The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human Vγ9Vδ2 T cells.
Sandstrom A; Peigné CM; Léger A; Crooks JE; Konczak F; Gesnel MC; Breathnach R; Bonneville M; Scotet E; Adams EJ
Immunity; 2014 Apr; 40(4):490-500. PubMed ID: 24703779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
